RAFA Quote, Financials, Valuation and Earnings

Cocrystal Pharma has a net margin of -- compared to Rafarma Pharmaceuticals's net margin of --. Rafarma Pharmaceuticals's return on equity of -- beat Cocrystal Pharma's return on equity of --.

Rafarma Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Cocrystal Pharma has an analysts' consensus of $8.33 which suggests that it could grow by 463.06%. Given that Cocrystal Pharma has higher upside potential than Rafarma Pharmaceuticals, analysts believe Cocrystal Pharma is more attractive than Rafarma Pharmaceuticals.

Rafarma Pharmaceuticals has a beta of 0.976, which suggesting that the stock is 2.411% less volatile than S&P 500. In comparison Cocrystal Pharma has a beta of 2.347, suggesting its more volatile than the S&P 500 by 134.714%.

Rafarma Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cocrystal Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals pays -- of its earnings as a dividend. Cocrystal Pharma pays out -- of its earnings as a dividend.

Rafarma Pharmaceuticals quarterly revenues are --, which are smaller than Cocrystal Pharma quarterly revenues of --. Rafarma Pharmaceuticals's net income of -- is lower than Cocrystal Pharma's net income of -$4.9M. Notably, Rafarma Pharmaceuticals's price-to-earnings ratio is -- while Cocrystal Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals is -- versus 7.49x for Cocrystal Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Rafarma Pharmaceuticals's net margin of -49.65%. Rafarma Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Rafarma Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 39.8%. Given that NovaBay Pharmaceuticals has higher upside potential than Rafarma Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Rafarma Pharmaceuticals.

Rafarma Pharmaceuticals has a beta of 0.976, which suggesting that the stock is 2.411% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.363%.

Rafarma Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Rafarma Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Rafarma Pharmaceuticals's net income of -- is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Rafarma Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PDS Biotechnology has a net margin of -- compared to Rafarma Pharmaceuticals's net margin of --. Rafarma Pharmaceuticals's return on equity of -- beat PDS Biotechnology's return on equity of --.

Rafarma Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand PDS Biotechnology has an analysts' consensus of $8.13 which suggests that it could grow by 544.84%. Given that PDS Biotechnology has higher upside potential than Rafarma Pharmaceuticals, analysts believe PDS Biotechnology is more attractive than Rafarma Pharmaceuticals.

Rafarma Pharmaceuticals has a beta of 0.976, which suggesting that the stock is 2.411% less volatile than S&P 500. In comparison PDS Biotechnology has a beta of 1.676, suggesting its more volatile than the S&P 500 by 67.622%.

Rafarma Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PDS Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals pays -- of its earnings as a dividend. PDS Biotechnology pays out -- of its earnings as a dividend.

Rafarma Pharmaceuticals quarterly revenues are --, which are smaller than PDS Biotechnology quarterly revenues of --. Rafarma Pharmaceuticals's net income of -- is lower than PDS Biotechnology's net income of -$10.7M. Notably, Rafarma Pharmaceuticals's price-to-earnings ratio is -- while PDS Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals is -- versus -- for PDS Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.

Tonix Pharmaceuticals Holding has a net margin of -- compared to Rafarma Pharmaceuticals's net margin of -856.24%. Rafarma Pharmaceuticals's return on equity of -- beat Tonix Pharmaceuticals Holding's return on equity of -138.47%.

Rafarma Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $406.67 which suggests that it could grow by 1916.2%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Rafarma Pharmaceuticals, analysts believe Tonix Pharmaceuticals Holding is more attractive than Rafarma Pharmaceuticals.

Rafarma Pharmaceuticals has a beta of 0.976, which suggesting that the stock is 2.411% less volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 2.226, suggesting its more volatile than the S&P 500 by 122.624%.

Rafarma Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend.

Rafarma Pharmaceuticals quarterly revenues are --, which are smaller than Tonix Pharmaceuticals Holding quarterly revenues of $2.6M. Rafarma Pharmaceuticals's net income of -- is lower than Tonix Pharmaceuticals Holding's net income of -$22.1M. Notably, Rafarma Pharmaceuticals's price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals is -- versus 2.53x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.